Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CNVN 202

Drug Profile

CNVN 202

Alternative Names: DOTAP-Chol-fus1; DOTAP-Cholesterol-Fus1 liposome complex; FUS1 cancer gene therapy; INGN-401; Oncoprex

Latest Information Update: 17 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Genprex
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action FUS1 tumour suppressor protein stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preclinical Breast cancer

Most Recent Events

  • 11 Sep 2019 Preclinical trials in Breast cancer in USA (IV) before September 2019
  • 11 Sep 2019 Pharmacodynamics data from an experimental study in Breast cancer released by Genprex
  • 03 Sep 2019 Genprex announces intention to file an IND to a regulatory body for Non-small cell lung cancer, in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top